AIM ImmunoTech (AIM) Accumulated Expenses (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Accumulated Expenses came in at $671000.0 in Q1 2026, up 67000.0% YoY from N/an in Q1 2025, and up 207.8% on a QoQ basis from $218000.0 in Q4 2025.
AIM ImmunoTech (AIM) Accumulated Expenses (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of Accumulated Expenses data on file, last reported at $671000.0 in Q1 2026.
- Quarterly Accumulated Expenses rose 67000.0% year-over-year to $671000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $671000.0 (up 67000.0% YoY) and the FY2025 annual result came in at $218000.0, down 64.03% from the prior year.
- Accumulated Expenses grew to $671000.0 in Q1 2026, from $218000.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $2.0 million in Q4 2023 to a low of $1000.0 in Q2 2024.
- A 5-year average of $516058.8 and a median of $502000.0 in 2022 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 80500.0% — and 2025, when it sank 99.93%.
- Tracing AIM's Accumulated Expenses over 5 years: stood at $806000.0 in 2022, then soared by 146.4% to $2.0 million in 2023, then plunged by 69.49% to $606000.0 in 2024, then plunged by 64.03% to $218000.0 in 2025, then jumped by 207.8% to $671000.0 in 2026.
- The last three Accumulated Expenses figures came in at $671000.0 (Q1 2026), $218000.0 (Q4 2025), and $17000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | AIM ImmunoTech | 4.43 Mn | -5.53 Mn | 21,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 586,000.00 |
| Mar 31, 2026 | 671,000.00 |
| Dec 31, 2025 | 218,000.00 |
| Sep 30, 2025 | 17,000.00 |
| Jun 30, 2025 | 573,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 606,000.00 |
| Sep 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 1,000.00 |
| Mar 31, 2024 | 1.45 Mn |
| Dec 31, 2023 | 1.99 Mn |
| Sep 30, 2023 | 29,000.00 |
| Jun 30, 2023 | 528,000.00 |
| Mar 31, 2023 | 17,000.00 |
| Dec 31, 2022 | 806,000.00 |
| Sep 30, 2022 | 33,000.00 |
| Jun 30, 2022 | 502,000.00 |
| Mar 31, 2022 | 328,000.00 |
| Dec 31, 2021 | 1,000.00 |
| Sep 30, 2021 | 362,000.00 |